This is a working overview of Angiotensin IV analog, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-17 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
The Ms. Pat Show is an American television sitcom created by Jordan E. Cooper and Patricia "Ms. Pat" Williams that premiered on the streaming service BET+ on August 12, 2021. The show is based on the comedy and life story of comedian Ms. Pat as a convicted felon from the streets of Atlanta turned reluctant suburban mother. The series has received nominations for 4 Primetime Emmy Awards for Outstanding Directing for a Comedy Series.
The white shark has a stocky, torpedo-shaped body with a short, cone-shaped snout. Its long gill slits do not reach around the head. It has a large triangular first dorsal fin, which partly lines up with the pectoral fins, and a tiny second dorsal fin. The tail fin has two lobes of similar size and a single ridge or keel, and the anal fin is tiny. The white shark has a countershaded coloration for camouflage; being dark on top, usually blue-gray or gray-brown, with a white underside. It also has black tips on the underside of the pectoral fins. There is evidence that the species can change pigments, adding dark pigment or melanin to blotches of white over the course of months. The skin is covered in dermal denticles (tooth-like scales), which are proportionally smaller than in other sharks and have a three-to-five-ridged surface, with each ridge having tips that point backwards.
The tension of the chain that does the cutting is adjusted so that it neither binds on, nor comes loose from the guide bar. The tensioner is either operated by turning a screw or a manual wheel. The tensioner is either in a lateral position underneath the exhaust or integrated into the clutch cover. Lateral tensioners have the advantage that the clutch cover is easier to mount, but the disadvantage that it is more difficult to reach nearby the bar. Tensioners through the clutch cover are easier to operate, but the clutch cover is more difficult to attach. When turning the screw, a hook in a bar hole moves the bar either out (tensioning) or in, making the chain loose. Tension is correct when it can be moved easily by hand and is not loose on the bar. When tensioning, hold the bar nose up and pull the bar nuts tight. Otherwise, the chain might derail. The underside of each link features a small, metal finger called a "drive link", which locates the chain on the bar, helps to carry lubricating oil around the bar, and engages with the engine's drive sprocket inside the body of the saw. The engine drives the chain around the track by a centrifugal clutch, engaging the chain as engine speed increases under power, but allowing it to stop as the engine speed slows to idle speed. Consistent improvement to overall chainsaw design, including adding safety features, has taken place over the years. These include chain-brake systems, better chain design, and lighter, more ergonomic saws, including fatigue-reducing antivibration systems.
Sources: en.wikipedia.org
subcellular localization 1. The subdivision of the interior of a cell into functionally distinct spaces or compartments (e.g. membrane-bound organelles) and the delegation of particular cellular functions and activities to these particular spaces. 2. The determination by any of various laboratory methods (e.g. fluorescent labelling) of the precise location(s) within a cell where a specific molecule has occupancy, or at which a specific activity occurs.
All nanotubes are expected to be very good thermal conductors along the tube, exhibiting a property known as "ballistic conduction", but good insulators lateral to the tube axis. Measurements show that an individual SWNT has a room-temperature thermal conductivity along its axis of about 3500 W·m−1·K−1; compare this to copper, a metal well known for its good thermal conductivity, which transmits 385 W·m−1·K−1. An individual SWNT has a room-temperature thermal conductivity lateral to its axis (in the radial direction) of about 1.52 W·m−1·K−1, which is about as thermally conductive as soil. Macroscopic assemblies of nanotubes such as films or fibres have reached up to 1500 W·m−1·K−1 so far. Networks composed of nanotubes demonstrate different values of thermal conductivity, from the level of thermal insulation with the thermal conductivity of 0.1 W·m−1·K−1 to such high values. That is dependent on the amount of contribution to the thermal resistance of the system caused by the presence of impurities, misalignments and other factors. The temperature stability of carbon nanotubes is estimated to be up to 2800 °C in vacuum and about 750 °C in air. Crystallographic defects strongly affect the tube's thermal properties. Such defects lead to phonon scattering, which in turn increases the relaxation rate of the phonons. This reduces the mean free path and reduces the thermal conductivity of nanotube structures. Phonon transport simulations indicate that substitutional defects such as nitrogen or boron will primarily lead to the scattering of high-frequency optical phonons.
=== 26 July === Russian forces captured the village of Lozuvatske in Donetsk Oblast, 24 kilometers east of Pokrovsk. The FSB announced the arrest of a suspect in the 24 July car bombing in Moscow who had been extradited from Turkey, claiming that he was a Russian national who carried out the attack on behalf of Ukrainian intelligence. Explosions were reported at Saky airfield in Crimea, and a drone attack on Sevastopol was reported. Russian authorities claimed that 21 drones were shot down over Bryansk Oblast.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.